medigraphic.com

2012, Number 1

<< Back Next >>

Rev Hematol Mex 2012; 13 (1)

Diabetes as a prognostic marker in Acute Lymphoblastic leukemia

Ramos-Peñafiel CO, Olarte-Carrillo I, Martínez-Tovar A, Castellanos-Sinco H, Rozen-Fuller E, Kassack-Ipiña JJ, Collazo-Jaloma J, Martínez-Murillo C

Language: Spanish
References: 27
Page: 5-10
PDF size: 97.48 Kb.


ABSTRACT

Background: Acute lymphoblastic leukemia in one of the most frequent causes of cancer-related deaths. Recently Diabetes has been associated with an increased risk of occurrence of malignant neoplasm mainly in liver and pancreas. The treatment has also been associated with the tumor response, favorably or unfavorably.
Material and Method: Retrospective, descriptive study in patients with novo acute lymphoblastic leukemia treated since December 2007. A comparison was made between Diabetic and Non-Diabetic patients in both treatment response and clinical variables.
Results: 154 Patients were studied, 6 with Diabetes, 5 diabetes type 2 and 1 Diabetes type 2. The median age was 29 years (29 for non Diabetic and 44 for Diabetic). Both groups had the same frequency of high-risk leukemia (66.5%). The good steroid response (33.7% vs 83%), complete remission (64.1% vs 83%) and overall survival was stadisticaly better in Diabetic patients ((p › 0.002).
Conclusion: The difference between the results in diabetic patients could be related with the use of metformin. An assay in vitro and in vivo showed is effectiveness in tumor growth by blocking signaling pathways (mTOR) and arresting the cell cycle in phase G1/G0 of cell cycle. Its effect as part of the chemotherapeutic treatment has not yet been described in hematologic malignancies.


REFERENCES

  1. Tirado-Gómez L, Mohar-Betancourt A. Epidemiologia de las neoplasias hemato-oncológicas. Cancerología 2007;2:109-120.

  2. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29 (5):532- 543.

  3. Olaiz- Fernández G, Rojas R, Aguilar-Salinas CA, Rauda J, Villalpando S. Diabetes mellitas en adultos mexicanos. Resultados de la Encuesta Nacional de Salud 2000. Salud Publica Mex 2007;49(S3):5331-5337.

  4. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin. A retrospective cohorte study in type 2 diabetic patients. Diabetes Obes metab 2011 [Epob ahead of print].

  5. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitas as a risk factor for cancer: stress or viral etiology? Infect Disord Drug Targets 2008;8(2):76-87.

  6. Nagel JM, Staffa J, Renner-Muller I, Horts D, Vogeser M, Langkamp M, et al. Insulin Glargine and NPH Insulin increase to a Similar Degree Epitelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice. Horm cancer 2010;1(6):320-330.

  7. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, et al. Cancer risk Associated with Insulin Glargine hmong Adult type 2 Diabetes Patients- A Nationwide Cohort study. PLos One 2011;6(6): e21368 [Epub ahead of print].

  8. Schmidt S, Rainer J, Riml S, Pioner C, Jesacher S, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood.2008;107:2061-2069.

  9. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL):analysis of the GIMEMA 0496 protocol.Blood 2005;105:3434-3441.

  10. Jabbour E, Faderl S. Adult acute lymphoblastic leukemia. Mayo Clinic Proceedings 2005;80(11):1517.

  11. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology 2011;25(4): 328-335.

  12. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia- positive acute lymphoblastic leukemia. Leuk Lymphoma 2011;52(S1):81-91.

  13. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, et al. Targated inhibition of mTORC1 and mTORC2 by active-site mTor inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011;25(5):781-791.

  14. Mullihgan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Resp 2011;17(3):396-400.

  15. Sun G, Kashyap SR. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab 2011;270-281.

  16. Shiratsuchi I, Akagi Y, Kawahara A, Kinugasa T, Romeo K, Yoshida T, et al. Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res 2011;31(7): 2541-2545.

  17. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between Diabetes Mellitus and Breast Cancer Risk: a Meta-analysis of the literature. Asian Pac J Cancer Prev 2011;12(4):1061-1065.

  18. Li CI, Daling JR, Tang MT, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat. 2011;125(2):545-551.

  19. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127(4):1044-1050.

  20. Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn 2011;121(3):81-87.

  21. Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 2011;43(8):519-523.

  22. Schott S, Bierhaus A, Schuetz F, Beckhove P, Schneeweiss A, Sohn C, Dom. Therapeutic effects of metformin in breast cancer: involvement of the immune system?. Cancer Immunol Immunother. 2011;60(9):1221-1225.

  23. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the Benefit of metformin use in cancer treatment. BMC Med 2011; 9:33.

  24. Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. Hormones 2011;10 (1):5-15.

  25. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46(1): 2369- 2380.

  26. Hirsch HA, Iliopoulos D, Tsichilis PN, Struhl K. Metformin selectively targets cancer stem cell, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69(19): 7507-7511.

  27. Iliopoulos D, Hirsch HA, Sthruhl K. Metformin decreases the dose of chemotherapy for oprolongng tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71(9):3196-3201.




2020     |     www.medigraphic.com